AGIOS PHARMACEUTICALS, INC. Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value
AGIOS PHARMACEUTICALS, INC. (AGIO) had Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value of $143.40 million as of 2016-09-30, per its 10-Q filed 2016-11-03.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue · last filed 2016-11-03
- 2016-09-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value $143.40M.
- 2016-06-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value $20.30M.
- 2016-03-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value $101.60M.
- 2015-12-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value $207.40M.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value |
|---|---|
| 2016-09-30 | $143.40M 10-Q · filed 2016-11-03 |
| 2016-06-30 | $20.30M 10-Q · filed 2016-08-08 |
| 2016-03-31 | $101.60M 10-Q · filed 2016-05-09 |
| 2015-12-31 | $207.40M 10-Q · filed 2016-11-03 |
| 2015-09-30 | $9.60M 10-Q · filed 2015-11-06 |
| 2015-06-30 | $16.70M 10-Q · filed 2015-08-07 |
| 2015-03-31 | $42.70M 10-Q · filed 2015-05-11 |
| 2014-12-31 | $236.90M 10-Q · filed 2015-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |